Market Overview

Goldman Sachs Raises PT on Salix Pharmaceuticals to $46

Goldman Sachs has raised the price target on Salix Pharmaceuticals from $35 to $46 and maintains its Neutral rating.

Posted-In: Goldman SachsPrice Target Pre-Market Outlook Analyst Ratings

 

Related Articles (SLXP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters